Preclinical Evaluation of virus-like particle Vaccine Against Carbonic Anhydrase IX Efficacy in a Mouse Breast Cancer Model System
-
Published:2024-01-13
Issue:5
Volume:66
Page:1206-1219
-
ISSN:1073-6085
-
Container-title:Molecular Biotechnology
-
language:en
-
Short-container-title:Mol Biotechnol
Author:
Kalniņa ZaneORCID, Liekniņa Ilva, Skeltona Vendija, Akopjana Ināra, Kazāks Andris, Tārs Kaspars
Funder
European Regional Development Fund
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71, 209–249. 2. Couzin-Frankel, J. (2013). Breakthrough of the year 2013. Cancer immunotherapy. Science, 342, 1432–1433. 3. Antonarelli, G., Corti, C., Tarantino, P., Ascione, L., Cortes, J., Romero, P., Mittendorf, E. A., Disis, M. L., & Curigliano, G. (2021). Therapeutic cancer vaccines revamping: Technology advancements and pitfalls. Annals of Oncology, 32, 1537–1551. 4. Buonaguro, L., & Tagliamonte, M. (2020). Selecting target antigens for cancer vaccine development. Vaccines (Basel). https://doi.org/10.3390/vaccines8040615 5. Pumpens, P., Renhofa, R., Dishlers, A., Kozlovska, T., Ose, V., Pushko, P., Tars, K., Grens, E., & Bachmann, M. F. (2016). The True Story and Advantages of RNA Phage Capsids as Nanotools. Intervirology, 59, 74–110.
|
|